Lead Product(s) : ISM3312
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Insilico Medicine Announces IND Approval of Oral 3CLpro Inhibitor ISM3312 for COVID-19
Details : ISM3312 is a highly selective 3CLpro inhibitor with a novel molecular structure optimized from compounds designed by Chemistry42, Insilico’s generative chemistry AI platform for the treatment of COVID-19.
Product Name : ISM3312
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2023
Lead Product(s) : ISM3312
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable